T1	Participants 180 241	HIV-infected patients initiating antiretroviral therapy (ART)
T2	Participants 384 620	106 ART-naive HIV-infected subjects who were randomized to receive efavirenz (EFV) + zidovudine/lamivudine (n = 32) or lopinavir/ritonavir (LPV/r) + zidovudine/lamivudine induction (n = 74) for 24-48 weeks followed by LPV/r monotherapy.
T3	Participants 1375 1465	Subjects with lower baseline CD4 T cell count, non-black race, and higher baseline glucose
T4	Participants 1581 1599	ART-naive subjects
